nature.com search

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Search
My Account Login

nature
search

advanced

where the list of authors contains where the title contains

Refine your results by…

volume

start page / article no.

Filters

Filter By:

Article type

Check one or more article types to show results from those article types only.

Research (3)

Journal

Check one or more journals to show results from those journals only.

Cell Death & Disease (3)

Choose more journals

Subject Check one or more subjects to show results from those subjects only.

Chemotherapy (1)
Combination drug therapy (1)
Non-small-cell lung cancer (1)
Pharmacokinetics (1)
Preclinical research (1)

Date

Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
In the last year
Last 2 years
Last 5 years

Custom date range

Sort by Relevance

Choose a way to sort results.

Relevance
Date — most recent
Date — oldest first

Loading Filters

Showing 1–3 of 3 results

Loading Filters

Research | 19 September 2013 | Open
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells
- M-C Chen
- , C-H Chen
- , J-C Wang
- , A-C Tsai
- , J-P Liou
- , S-L Pan
- & C-M Teng
Cell Death & Disease 4 , e810–e810

Rights & permissionsfor article The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells . Opens in a new window.
Research | 10 April 2014 | Open
Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009
- I-N Hsieh
- , J-P Liou
- , H-Y Lee
- , M-J Lai
- , Y-H Li
- & C-R Yang
Cell Death & Disease 5 , e1166–e1166

Rights & permissionsfor article Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009 . Opens in a new window.
Research | 10 April 2014 | Open
Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib
- A-C Tsai
- , C-Y Wang
- , J-P Liou
- , H-C Pai
- , C-J Hsiao
- , J-Y Chang
- , J-C Wang
- , C-M Teng
- & S-L Pan
Cell Death & Disease 5 , e1162–e1162

Rights & permissionsfor article Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib . Opens in a new window.

Search

Article Search

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

nature.com sitemap

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
Nano
Protocol Exchange
Nature Index

Publish with us

Guide to Authors
Guide to Referees
Editorial policies
Open access
Reprints & permissions

Researcher services

Research data
Language editing
Scientific editing
Nature Masterclasses
Nature Research Academies

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Career development

Nature Careers
Nature Conferences
Nature events

Regional websites

Nature China
Nature India
Nature Japan
Nature Korea
Nature Middle East

Legal & Privacy

Privacy Policy
Use of cookies
Manage cookies/Do not sell my data
Legal notice
Accessibility statement
Terms & Conditions
California Privacy Statement

Refine your results by…

Filters ​

Filter By:

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells

Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009

Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib

Search

Quick links

Filters